Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2025 | $60.00 | Buy | TD Cowen |
| 3/13/2025 | $40.00 | Buy | Citigroup |
| 9/13/2024 | $40.00 | Buy | Jefferies |
| 5/3/2024 | $34.00 | Overweight | Wells Fargo |
| 12/29/2021 | $37.00 → $34.00 | Buy | B of A Securities |
TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00
Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00
LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biop
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regis
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regis
– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)